IFP Advisors’s Ascendis Pharma A/S ASND Stock Holding History

IFP Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$115K	Buy	431 +419	+3,492%	+$97.9K	﹤0.01%	1883
2026 Q1	$2.75K	Buy	12 +5	+71%	+$1.12K	﹤0.01%	3832
2025 Q4	$1.49K	Buy	7 +1	+17%	+$207	﹤0.01%	3941
2025 Q3	$1.19K	Buy	+6	New	+$1.12K	﹤0.01%	3882
2025 Q1	–	Sell	-1	Closed	-$138	–	4325
2024 Q4	$138	Buy	+1	New	+$131	﹤0.01%	3905

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

IFP Advisors's ASND Position: Q2 2026 in Review

IFP Advisors increased its Ascendis Pharma A/S (ASND) stake by 3,492% in Q2 2026, buying an estimated $97.9K and bringing the position to 431 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #1883.

IFP Advisors first reported a position in ASND in Q4 2024 and has held it in 5 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

IFP Advisors held 431 shares of Ascendis Pharma A/S worth $115K as of Q2 2026.
IFP Advisors bought 419 Ascendis Pharma A/S shares in Q2 2026, an estimated $97.9K.
Ascendis Pharma A/S made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #1883 holding.
IFP Advisors first reported a position in Ascendis Pharma A/S in Q4 2024 and has held it in 5 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.